Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Approved
Sponsor : Norgine
Deal Size : $271.6 million
Deal Type : Licensing Agreement
Fennec and Norgine License PEDMARQSI for Europe, Australia, New Zealand
Details : Norgine will commercialize Pedmarqsi (sodium thiosulfate) in Europe, Australia, and New Zealand, the first approved therapy in the EU and UK to prevent cisplatin-induced ototoxicity.
Brand Name : Pedmarqsi
Molecule Type : Small molecule
Upfront Cash : $43.4 million
March 18, 2024
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Approved
Sponsor : Norgine
Deal Size : $271.6 million
Deal Type : Licensing Agreement
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Approved
Sponsor : Petrichor
Deal Size : $20.0 million
Deal Type : Financing
Fennec Announces Incremental $5 Million Investment from Petrichor
Details : The net proceeds will be used by the company for the commercialization of Pedmark (sodium thiosulfate), the only approved therapy for reducing the risk of hearing loss in pediatric cancer patients who receive treatment with platinum-based chemotherapy.
Brand Name : Pedmark
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 05, 2023
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Approved
Sponsor : Petrichor
Deal Size : $20.0 million
Deal Type : Financing
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Pedmarqsi™ (sodium thiosulfate) is the only FDA approved intravenous therapy, to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors.
Brand Name : Pedmarqsi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 31, 2023
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Pedmark® (sodium thiosulfate) is the only FDA approved intravenous therapy, to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors.
Brand Name : Pedmark
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 31, 2023
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Pedmark® (sodium thiosulfate) is the only FDA approved intravenous therapy, to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors.
Brand Name : Pedmark
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 25, 2023
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase III
Sponsor : Petrichor Healthcare
Deal Size : $25.0 million
Deal Type : Financing
Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor
Details : Under the terms of the agreement, an additional is to be funded upon the potential U.S. Food and Drug Administration approval of PEDMARK (sodium thiosulfate) by September 30, 2022 and satisfaction of other closing conditions.
Brand Name : Pedmark
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 22, 2022
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Sponsor : Petrichor Healthcare
Deal Size : $25.0 million
Deal Type : Financing
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase III
Sponsor : Petrichor Healthcare Capital Management
Deal Size : $45.0 million
Deal Type : Financing
Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor
Details : PEDMARK (sodium thiosulfate), has been studied by cooperative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, the clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. Both studies have been completed.
Brand Name : Pedmark
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 01, 2022
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Sponsor : Petrichor Healthcare Capital Management
Deal Size : $45.0 million
Deal Type : Financing
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : 87% of patients who experienced ototoxicity in their placebo-treated ear were protected from ototoxicity in their DB-020, a novel, proprietary formulation of sodium thiosulfate treated ear.
Brand Name : DB-020
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 28, 2022
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PEDMARK is a small molecule, unique formulation of STS, is administered 6 hours post completion of cisplatin infusion in an intravenous bolus dose over 15 minutes, has potential to reduce the incidence of chemotherapy-induced hearing loss.
Brand Name : Pedmark
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 27, 2022
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PEDMARK™ (a unique formulation of sodium thiosulfate), is currently under evaluation by EMA, as an essential chemotherapeutic agent for many pediatric malignancies also has received breakthrough therapy and fast track designation.
Brand Name : Pedmark
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 24, 2022
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
